Venetoclax or Ruxolitinib in Pre-Transplant Conditioning Lowers the Engraftment Barrier by Different Mechanisms in Allogeneic Stem Cell Transplant Recipients

Venetoclax or Ruxolitinib in Pre-Transplant Conditioning Lowers the Engraftment Barrier by Different Mechanisms in Allogeneic Stem Cell Transplant Recipients

Allogeneic stem cell transplantation (alloSCT) is utilised to cure haematological malignancies through a combination of conditioning regimen intensity and immunological disease control via the graft versus tumour (GVT) effect. Currently, conventional myeloablative chemotherapeutic or chemoradiation...

Full description

Bibliographic Details
Main Authors: Joanne E. Davis, Kelei Du, Mandy J. Ludford-Menting, Ashvind Prabahran, Eric Wong, Nicholas D. Huntington, Rachel M. Koldej, David S. Ritchie
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Immunology
Subjects:
venetoclax
ruxolitinib
reduced intensity conditioning
graft versus tumour effect
MHC class-II
graft versus host disease
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.749094/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.749094/full

Similar Items